Meeting Materials
Annual Report
View an enhanced version of our Annual Report.
Proxy Statement
View an enhanced version of our Proxy Statement.
View an enhanced version of our Annual Report.
View an enhanced version of our Proxy Statement.
* Request paper copies of the above proxy materials online now, by email or by phone by dialing 866-648-8133.
Please be sure to vote your shares. Vote online or by phone by dialing 866-430-8263.
June 3, 2024
9:00 AM ET
Cabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies that have the potential to provide a deep and durable, perhaps curative, treatment for patients with autoimmune diseases. The CABA™ platform encompasses two strategies: the CARTA (Chimeric Antigen Receptor T cells for Autoimmunity) strategy, with CABA-201, a 4-1BB-containing fully human CD19-CAR T, as the lead product candidate being evaluated in lupus nephritis and systemic lupus erythematosus without renal involvement, and the CAART (Chimeric AutoAntibody Receptor T cells) strategy, with multiple clinical-stage candidates, including DSG3-CAART for mucosal pemphigus vulgaris and MuSK-CAART for MuSK myasthenia gravis. The expanding CABA™ platform may offer potentially curative therapies for patients with a broad range of autoimmune diseases. Cabaletta Bio’s headquarters and labs are located in Philadelphia, PA.